News

ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee ...
Will Pfizer's Non-COVID Drugs Drive Sales Again This Earnings Season?
Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in ...
Morningstar9d
ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
This includes ABRYSVO® (Respiratory Syncytial Virus Vaccine), which in October 2024, the U.S. Food and Drug Administration approved for the prevention of RSV-associated LRTD in adults aged 18 to ...
Seeking Alpha9d
ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
“We are proud that ABRYSVO has the broadest indication among RSV vaccines, covering older adults, adults 18 and older at heightened risk of severe disease, and pregnant women to help protect ...
PharmExec8d
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to ...
24/7 Wall St. on MSN1d
Prediction: 1 Biotech Stock That Could Surpass Pfizer by 2030
Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...
Managed Healthcare Executive4d
A Win for Adult RSV Vaccination Amid Vaccine Uncertainty, Hesitancy
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...
pharmaphorum9d
There's good news for RSV jab firms at delayed ACIP meeting
The Advisory Committee on Immunisation Practices (ACIP) has voted to widen the recommendations on the use of RSV shots to ...
Morningstar25d
European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49 Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC ...